

Available online on 15.09.2017 at <http://jddtonline.info>**Journal of Drug Delivery and Therapeutics**

Open Access to Pharmaceutical and Medical Research

© 2011-17, publisher and licensee JDDT, This is an Open Access article which permits unrestricted non-commercial use, provided the original work is properly cited

Open  Access

Research Article

SUPERFICIAL ANTICANDIDOSIC ACTIVITY OF LEAVES OF COMBRETUM RACEMOSUM P. BEAUV. (COMBRETACEAE) EXTRACTS**KAMOU Kamou Richard^{1,2*}, NANGA Yessé Zinzendorf², OUATTARA Abou³, KAMBOU Sansan Philippe⁴, GNAHOUE Gouéh⁵, BAH Calixte¹ and COULIBALY Adama¹**¹University Felix Houphouët-Boigny of Cocody, UFR Biosciences, Laboratory of Pharmacodynamic-Biochemistry, 22 BP 582 Abidjan 22, Ivory Coast²University Felix Houphouët-Boigny of Cocody, UFR of Pharmaceutical and Biological Sciences, Laboratory of Bacteriology-Virology, 22 BP 582 Abidjan 22, Ivory Coast³University Jean Lorougnon Guede of Daloa, UFR Agroforestry, Department of Biochemistry and microbiology, BP 150 Daloa, Ivory Coast⁴University Felix Houphouët-Boigny of Cocody, UFR of Médical Sciences, Laboratory of Médical Biochemistry, 01 BP 240 Abidjan 01, Ivory Coast⁵Teaching Training School (ENS) of Cocody, Laboratory of Biochemistry-Microbiology (SVT Section), 08 BP 10 Abidjan 08, Ivory Coast**ABSTRACT**

This preliminary work consists in evaluating the superficial anticandidic activity of the leaves of *Combretum racemosum* P. Beauv in humans. To this end, we first demonstrated bioactive compounds of five (5) crude extracts (aqueous and hydro-organic 70%) from *C. racemosum*. Then, and finally, we have separately evaluated the superficial anticandidic activity of these extracts on *Candida albicans*, a species of genus *Candida*, mostly encountered in superficial human candidiasis. *C. albicans* was found to be sensitive to the five extracts tested. This partly justifies the use of *C. racemosum* in traditional medical practice against superficial microbial diseases. For these extracts, the Inhibitory Minimum Concentrations (MIC) recorded ranged from 7.8125 mg/mL to 62.550 mg/mL; While Fungicide Minimum Concentrations (CMF) range from 31.25 ± 0.00 mg/mL to 62.550 mg/mL. Concentrations for Fifty Percent Inhibition (IC₅₀) range from 0.930 mg/mL to 3.861 mg/mL. The hydroethanolic macerated extract 70% (Eeth 70%) is the most active fraction on *C. albicans* (CMF = 7.8125 ± 0.00 mg/mL, IC₅₀ = 0.941 ± 0.009 mg/mL) compared to the total of the five crude extracts tested. The preliminary phytochemical screening of the five crude extracts revealed the presence of alkaloids, saponins, terpenoids steroids and tannins (catechics and gallics) at various levels of concentration in our study. Eeth 70%, the most active extract in our work, contains in medium concentrations the same active ingredients cited above. Finally, we note that the hydroethanolic macerated extract 70% is the most active fractions in this work. It may, however, subject to toxicological studies, be used in the treatment of the skin, the cutaneous appendages and the mucous membranes in humans.

Keywords: *Combretum racemosum*, phytochemical screening, superficial anticandidic**Article Info:** Received 28 June, 2017; Review Completed 28 Aug, 2017; Accepted 29 Aug, 2017; Available online 15 Sep, 2017**Cite this article as:**Kamou KR, Nanga YZ, Ouattara A, Kambou SP, Gnahoue G, Bahi C, Coulibaly A, Superficial anticandidic activity of leaves of *combretum racemosum* P. Beauv. (Combretaceae) extracts, *Journal of Drug Delivery and Therapeutics*. 2017; 7(5):53-60DOI: <http://dx.doi.org/10.22270/jddt.v7i5.1484>***Address for Correspondence**KAMOU Kamou Richard, University Felix Houphouët-Boigny of Cocody, UFR Biosciences, Laboratory of Pharmacodynamic-Biochemistry, 22 BP 582 Abidjan 22, Ivory Coast, E-mail: richardkamou@yahoo.fr**1. INTRODUCTION**

The skin, the cutaneous appendages and the mucous membranes constitute the first natural defenses of the living organism against external aggressions of any kind,

in particular the microbial invasions¹. They contain, in fact, physical, chemical and biological parameters, in particular microbial parameters, essential for the survival of the living body. Consequently, they require regular and rigorous hygiene, and in case of external microbial

aggressions, adequate and immediate medicinal treatments.

The genus *Candida* is a group of commensal yeast species of humans and other animals, opportunistic pathogens, keratinophilic and having an affinity for keratinized tissue to cause superficial and invasive candidiasis.

At the global level, for example in Central Africa, species of the genus *Candida* are at the forefront of opportunistic leprosy in healthy people and those living with HIV, and are the cause of pathological manifestations of AIDS². Moreover, in recent years, the incidence of previously unrepresented candidiasis species is responsible for the increased frequency of yeast infections³. As an indication, *Candida albicans* is today, the most pathogenic and wide spread *Candida*⁴. However, although it is the most widespread species, these other species defined as non-*albicans* have, in recent years, a higher prevalence related to ecology⁵.

Moreover, in Côte d'Ivoire in particular, a 2008 study in Abidjan on *C. albicans*, the most pathogenic and most frequently isolated *Candida*, showed that *C. albicans* accounted for 72.6% of the original strains vaginal disorders⁶.

The superficial candidiasis, the object of this study, is opportunistic infections due to yeasts of the genus *Candida*, which affect the epidermis of the skin, the cutaneous appendages and the mucous membranes⁷. They represent the most frequent and natural candidiasis in the intestine, folds and buttocks, especially in young children⁸. They are cosmopolitan, recurrent and recurring superficial fungal infections that are difficult to cure in some cases, do not threaten life, but cause physical discomfort for those affected and may be factors that contribute to serious diseases including HIV infections⁹. They often lead to deaths in immune compromised individuals because of recurrence and difficulties in curing some cases. Overall, the rate of the global population with superficial candidiasis ranges from 70% to 80%; babies, children and immune compromised persons are the first victims^{10, 11}. This frequency has increased steadily in recent years, with five to six recurrences a year. Moreover, the risk of complications of these infections in immune compromised subjects, for example indigestive candidiasis patients, is enormous and the mortality rate varies from 40 to 60%¹².

On the other hand, conventional modern medicines such as azoles, allylamines, equinocandins and polyenes are effective against fungal infections and are currently available on the market¹³. However, they are limited in number; costly, difficult to access by the poor and do not always correspond to the effective treatments for these diseases¹⁴. However, they consist of heavy drug treatments, not without undesirable side effects and constitute on the market, the main therapies used^{15; 16}. Another major problem with these modern medicines is the resistance that certain pathogenic organisms put in place against these drugs, which, moreover, have quite high toxicity a few times^{17; 18}.

All these factors listed above make it necessary to develop new, effective, low-toxicity medicines that are readily available to populations from all walks of life. This research would be based on plants, because they are an important source of an immense variety of bioactive molecules¹⁹. Moreover, these phytochemicals have multiple interests used in industry, food, cosmetology and dermatopharmacy. Among these molecules are alkaloids, coumarins, quinones, phenolic compounds, tannins, lignins, flavonoids and terpenes^{20; 21}.

On the international markets, demand for natural herbal medicines is also high. Today, according to the WHO, this demand is estimated at about 81% and represents for humanity, primary health care²². *Combretum racemosum* P. Beauv. could meet this demand. *Combretum racemosum* P. Beauv. is a very common shrub of the genus *Combretum* and widely used in African traditional medicine for its antimicrobial activities^{23; 24}. Several scientific studies have been carried out on species of the family *Combretaceae* of which it forms part²⁵. However, so far no special report has been made on *C. racemosum* against superficial candidiasis.

This work consisted in evaluating the superficial anticandidic activity of five crude extracts (aqueous and hydro-organic 70%) of *C. racemosum* in humans. In addition, a preliminary triphenochemical study of the various extracts was also carried out.

2. MATERIALS AND METHODS

2-1. Plant material

The plant material used consists of fresh leaves of *C. racemosum*. This plant is found in East Africa, in the forestry recruits of the Guineo-Congolese region, in Senegal and Cameroon. It is also found in southern Nigeria where, in view of its therapeutic utility, it bears the name "Ebi-odo" or "Rose de Noel"^{26; 27}. In Côte d'Ivoire, *C. racemosum* occurs in the southern forest zone; It is known under the vernacular name of betso (in the Attié language in the Department of Anyama) and calo wôrô (in the Bambara language). It is a large climbing vine or a sprouting shrub up to 25-30 m long.

The leaves, ovate or elliptic, acuminate and rounded at the base, average 10 cm in length and 5 cm in width. They include about 8 to 10 lateral ribs. The inflorescences, of the panicles of short speciform racemes, are remarkable for the white bract leaves, the terminal or axillary clusters of yellow flowers. The flowers have 5 free sepals and 5 petals. They have 6 to 7 fertile stamens, very long anthers and poricidal. The fruits, with four wings, are white- greenish or pinkish in the fresh state.

These leaves of *C. racemosum* are collected in June 2015 in the Department of Anyama (Côte d'Ivoire) and authenticated by Professor AKE Assi at the National Floristic Center of the University Félix Houphouët Boigny of Abidjan where samples are deposited Herbarium of the Plant under No. 19649, on 17 July 1985. These sheets were used to make powders and then the five crude extracts (aqueous and hydro-organic 70%).

2-2. Candidic isolates used

The candidotic isolate used is *Candida albicans* (13-304). *Candida albicans* is a commensal filamentous yeast of the skin and mucous membranes which, under special conditions, cause acute, subacute or chronic candidiasis of the skin, mucous membranes and more rarely visceral and generalized²⁸. Among the yeasts of the genus *Candida*, it is the most widespread but also the most pathogenic species of superficial candidiasis. It infects newborns, immune suppressed individuals, diabetics and surgical patients, as well as healthy people. For example, 75% of women have had vaginal candidiasis in *C. albicans* and 5% have chronic candidiasis²⁹.

The choice of *C. albicans* is made because of its majority (60%) involvement in superficial and invasive candidiasis.

Our strain of *C. albicans* (13-304) is supplied by the Laboratory of Mycology of the Institute Pasteur of Ivory Coast (IPCI). It is derived from the vaginal sampling of AIDS patients from infectious diseases.

2-3. Plant treatments and sampling

After identification, the leaves of *C. racemosum* are first thoroughly sorted and freed from foreign bodies. They are then washed with distilled water, cut and dried out of the sun and in the open air. After drying, they are sprayed using a Culatti type Mfc electric grinder. Finally, the fine powder obtained is stored in sterile, clean and dry bottles. The whole is kept away from moisture and at ambient temperature of the laboratory to serve the preparation of the five crude extracts (aqueous and hydro-organic 70%).

2-4. Preparation of aqueous crude extracts

The macerated aqueous crude extract (codified Eaq) is obtained according to the following method³⁰:

100 g of leaf powder are homogenized in 1 liter (1 L) of distilled water in a mixer at room temperature. The homogenate obtained is first drained through a square of white cloth. Then, double filtered on hydrophilic cotton (ref: 87071) and once on 3 mm wattman paper. The filtrate obtained is concentrated in an oven at 50 ° C. to give the macerated aqueous crude extract (Eaq).

The soaked aqueous crude extract (codified Edec) is obtained according to the following method³¹:

100 g of leaf powder is first dissolved in one liter (1 L) of cold distilled water in a beaker. The whole is then boiled for 15 minutes on a hot plate, and homogenized in a blender (Mixer) at room temperature. At the end of the homogenization, the homogenate obtained is first drained through a square of white cloth. Then, double filtered on hydrophilic cotton (ref.: 87071) and once on 3 mm wattman paper. The filtrate obtained is concentrated in an oven at 50° C.

The Eaq and the Edec obtained are finally stored in sterile, clean and dry bottles and then kept away from heat and humidity to be separately used for the evaluation of the bioactive compounds and the surface anticandidotic activity.

2-5. Preparation of the hydro-organic crude extracts 70%

The macerated hydroacetate extract 70% (codified Eace 70%) is prepared according to the following method³²:

100 g of leaf powder is dissolved in one liter (1 L) of a solution of cold water and pure ethyl acetate (300 mL of cold distilled water per 700 mL of pure ethyl acetate 99.5° G.L) and then homogenized in a blender. After homogenization in a blender at room temperature, each homogenate obtained is first filtered through a square of white cloth. Then, double filtered on hydrophilic cotton (ref: 87071) and once on 3 mm wattman paper. The filtrate obtained is concentrated in an oven at 50 ° C.

The macerated hydro-ethanolic crude extract 70% (codified Eeth 70%) and macerated hydro-methanolic crude extract 70% (codified Emet 70%) are prepared according to the preceding method³². However, the purity of ethanol is 96° G.L while that of methanol is 99.85° G.L.

The masses of Eace 70%, Eeth 70% and Emet 70% obtained are stored in sterile, clean, dry bottles then stored away from heat and humidity to be separately used For the evaluation of the bioactive compounds and then the superficial anticandidotic activity.

2-6. Phytochemical screening of the various *C. racemosum* extracts

The five crude extracts of *C. racemosum* are distinctly subjected to a phytochemical screening for secondary metabolites contained in the leaves of the plant³³. Each bioactive compound is demonstrated in accordance with the method of Mangambu et al.³⁴. It is a set of identification reactions and colored indicators based on the reduction (alkaline or basic) of the reagent mixture by the oxidizable groups of the bioactive compounds, leading to the formation of color reduction products which are a function of the environment. For each extract, 10 screening tests per colored reactions are carried out. Solutions with indicators have a positive reaction; This indicates the presence of bioactive compounds in the extracts and therefore in the leaves of *C. racemosum*.

2-7. Evaluation of the superficial anticandidotic activity of the various extracts

2-7.1. Preparation of culture media

Sabouraud agar (ref: Bio-RAD, batch: C8B2212, n° 74994) buffered to pH 5.7 is used for this test. The medium of culture is prepared according to the instructions of the manufacturer's protocol.

The incorporation of extracts of *C. racemosum* in Sabouraud agar is carried out using the method of double dilution of agar on slopes^{35; 36}. For each *C. racemosum* extract, each series consists of 10 test tubes. Eight (8) of these test tubes contain extract. And the other two tubes are considered as control tubes. Of these two (2) tubes, one extract was used as control for growth control of *C. albicans* while the other without *C. albicans* strain and without extract was used as a control for the sterility control of Sabouraud agar. The eight (8) test

tubes with concentrations ranging from 125 to 0.78 mg / mL are bound by a geometric reason of $\frac{1}{2}$. All the tubes are autoclaved at 121° C. for 15 minutes and then inclined at ambient temperature to allow the cooling and solidification of Sabouraud agar ³⁷. Ketoconazole is used as a drug control.

2-7.2. Anticandidosic test

The candidosic inoculum is prepared from culture of 48 hours of young colonies of *C. albicans*, previously isolated from Yeast glucose chloramphenicol (ref.: 51078, batch: 777666501) which is a microscopic fungal selective medium supplied by Biomedis. One (1) colony of *C. albicans* is removed and homogenized in 10 mL of sterilized distilled water to obtain a 100 germ suspension. On dilution to 1/10, 1 mL of this suspension is transferred and homogenized in 9 mL of sterilized distilled water to give a final volume of 10 mL to suspension 10^{-1} . The latter is stored for inoculation at the rate of 10 μ L per tube.

The anticandidosic test concerns the 8 test tubes and the growth control (Tc) control. Thousand (1000) cells of *C. albicans*, equivalent to 10 μ L, are seeded by transverse streaks tight until exhaustion; on Sabouraud agar medium prepared before hand ³⁸.

For each extract, all tests are carried out by triplicates. The cultures are incubated at 30 ° C. for 48 hours. They are used to determine the superficial anticandidosic activity.

2-8. Determination of the anticandidosic activity of the various extracts

This part concerns microbiological factors: colony counts of *C. albicans*, determination of antifungal parameters (MIC, CMF and IC_{50}) and the growth curve of *C. albicans*.

2-8.1. Enumeration of Candidate Colonies

After this incubation time, the colonies of *C. albicans* are first counted by direct counting with a colony counting pen (serial number of Cebeware 23382, brand Bel-Art), then, and finally, growth in 10 experimental tubes on the percent survival is evaluated, compared to 100% survival in the Tc growth control pilot tube ³⁹.

2-8.2. Determination of antifungal parameters

After counting the colonies, the value of each antifungal parameter is determined. Data processing allows for minimum values of inhibitory concentrations (MIC), fungicide concentration (CMF), graphically to determine on the activity curves of the extract 50% of the inhibition concentration values (IC_{50}) and activity report (CMF/CMI).

The MIC is here the concentration of extract of *C. racemosum* in the tube for which there was no visible growth with the naked eye. CMF is the concentration of extract which gives 99.99% inhibition as compared to the growth control tube. The IC_{50} is determined graphically from the sensitivity curve of *C. albicans* to each extract.

2.9. Statistical analysis

The values of the antifungal parameters of each extract are determined using the Graphpad software. The results are given as mean \pm SE (n = 4), using Colum Statistica.

3. RESULTS AND DISCUSSION

In this work, bioactive compounds (active ingredients) of the five crude extracts (aqueous and hydro-organic 70%) of *C. racemosum* leaves are demonstrated by phytochemical screening. The in-vitro anticandidosic activity of these extracts is also evaluated with respect to *C. albicans*.

3-1. Bioactive compounds

The results of the phytochemical screening of the five crude extracts of *C. racemosum* leaves are shown in table 1. Analysis of these results clearly reveals the presence in the five extracts of alkaloids, flavonoids, phenolic compounds, saponins, steroids, terpenoids and tannins (catechics and gallics) in varying degrees of concentration (table 1).

The 70% (70% Eeth) hydroethanolic crude extract contains alkaloids, saponins, steroids, terpenoids and tannins (catechic and gallic) at medium concentrations (table 1).

Table 1: Bioactive compounds of the five leaf extracts of *C. racemosum*

Chemical constituents		Aqueous extracts		Hydro-organic extracts		
		Eaq	Edec	Eace 70%	Eeth 70%	Emet 70%
Alkaloid	B	+	+	+	++	+++
	D	+	+	+	++	+++
Flavonoids		+	++	-	-	+
Phenolic compounds		+	++	-	-	+
Free quinone		-	-	-	-	-
Saponins		+	++	+	++	+++
Steroids		+	++	+++	++	+
Terpenoids		+	++	+++	++	+
Tannins	Cat	+	++	-	++	+
	Gal	+	+	-	++	+

Eaq: Macerated aqueous crude extract; Edec: Soaked aqueous crude extract; Eace 70 %: Crude Macerated hydro-ethyl acetate crude extract 70%; Eeth70 %: Macerated hydro-ethanolic crude extract 70%; Emet 70 %: Macerated hydro- methanolic crude extract 70%; B: Bouchardat; D: Dragendorff; Cat: Catechics; Gal: Gallics; -: Lack of bioactive compounds; +: Weak of bioactive compounds; ++: Medium concentration of bioactive compounds; +++: High concentration of bioactive compounds

By triphyochemical studies confirmed on *C. racemosum* extracts, similar results have been obtained by Harbone, Onocha et al. (a), Okwuosa et al. and Kamou et al.^{40; 41; 42; 43}. These results could confirm in part the use in traditional *C. racemosum* against microbial superficial infections. These compounds are already known for their antimicrobial activities^{44, 45, 46}.

McGaw et al., Have also demonstrated the presence of these secondary metabolites in a hydro-ethanolic crude extract (Eeth 70%)⁴⁷.

3-2. Superficial anticandidosic activity of the different extracts

The anticandidic activity of each *C. racemosum* crude extract was evaluated. The values of the antifungal parameters are determined (figure 1, table 2). Analysis of the experimental results shows that, compared with

growth control (TC) controls, there is a decrease in the number of *C. albicans* colonies in the test tubes as the concentration of each extract increases (figure 1). The curve that characterizes this decrease shows a decreasing rate (figure 1). Thus, our results show that the five (5) extracts tested are active at various levels ranging from 7.8125 ± 0.00 mg / mL to 62.5 ± 0.00 mg / mL and show anticandidic activity by inhibiting. The in-vitro growth of *C. albicans* in a dose-response relationship.

The sensitivity of *C. albicans* to each extract as well as the curve obtained make it possible to determine the different antifungal parameters of each extract, namely the Minimum Inhibitory Concentration (MIC), the Minimum Fungicidal Concentration (CMF), the Concentration for Fifty percent Inhibition (IC_{50}) as well as the activity report (CMF/CMI) (table 2).




Figure 1: Sensitivity of *C. albicans* to *C. racemosum* extracts

Table 2: Superficial anticandidosic activity of *C. racemosum* five crude extracts tested

Strain	Crude extracts	Anticandidosic parameters (mg/mL)			Activity report (CMF/CMI)	Effect (Fungicidal)
		CMI	CMF	IC_{50}		
<i>Candida albicans</i> (13-304)	Eaq	$31,25 \pm 0,00$	$31,25 \pm 0,00$	$1,903 \pm 0,015$	1	Fungicide
	Edec	$15,625 \pm 0,00$	$15,625 \pm 0,00$	$0,930 \pm 0,010$	1	Fungicide
	Eace 70%	$62,5 \pm 0,00$	$62,5 \pm 0,00$	$3,861 \pm 0,009$	1	Fungicide
	Eeth 70%	$7,8125 \pm 0,00$	$7,8125 \pm 0,00$	$0,941 \pm 0,009$	1	Fungicide
	Emet 70%	$31,25 \pm 0,00$	$31,25 \pm 0,00$	$0,946 \pm 0,005$	1	Fungicide
	Két	$0,0076 \pm 0,00$	$7,65 \times 10^{-3} \pm 0,00$	$4,653 \times 10^{-6} \pm 1,528 \times 10^{-8}$	1	Fungicide

Eaq: Macerated aqueous crude extract; Edec: Soaked aqueous crude extract; Eace 70 %: Macerated hydro-ethyl acetate crude extract 70%; Eeth 70 %: Macerated hydro-ethanolic crude extract 70%; Emet 70 %: Macerated hydro-methanolic crude extract 70%; Ket: ketoconazole, MIC: Minimum Inhibitory Concentration; CMF: Minimum Concentration Fungicide; IC_{50} : Concentration for Fifty percent Inhibition

The sensitivity of the *C. albicans* strain to the five extracts tested justifies in part the use in traditional *C. racemosum* P. Beauv. against microbial diseases. In separate studies evaluating phytochemical and antimicrobial properties of leaf extracts of *C. racemosum* validated, Onocha et al. (b) and Okwuosa et al., also showed the sensitivity of *C. albicans* to crude aqueous, ethyl acetate, methanolic and hexanic extracts

of *C. racemosum*^{48; 49}. The synergistic action of alkaloids, flavonoids, phenolic compounds, saponins, steroids, terpenoids and tannins at various degrees of concentration would be the basis of the anticandidosic activity observed in the five crude extracts in our study. Indeed, alkaloids, for example, are endowed with antimicrobial properties⁵⁰. Flavonoids, tannins and triterpenoids are recognized as antifungal molecules⁵¹.

Flavonoids are in particular responsible for the antiallergic, antiparasitic power and also inhibit the activation of the supplements^{52; 53}. Phenolic compounds have been found to have antibacterial and antifungal activities, and are indeed natural compounds widely distributed in the plant kingdom, which are of increasing importance, in particular because of their beneficial effects on health⁵⁴. They are also used as additives in the food, pharmaceutical and cosmetic industries⁵⁵.

The five extracts tested were fungicide on the strain of *C. albicans* studied. For the five extracts, the recorded MIC ranged between 7.8125 ± 0.00 mg/mL and 62.5 mg/mL for *C. albicans*; while CMF ranges from 7.8125 ± 0.00 mg/mL to 62.5 mg/mL. IC₅₀ range from 0.930 ± 0.010 mg/mL to 3.861 ± 0.009 mg/mL.

The macerated hydro-ethanolic extract 70% (Eeth 70%) is the most active fraction compared to the others on *C. albicans* (CMF = 31.25 ± 0.00 mg/mL, IC₅₀ = 1.910 ± 0.009 mg/mL). This activity is comparable to that of the reference drug ketoconazole tablet (CMF = $7.65 \times 10^{-3} \pm 0.00$ mg/mL, IC₅₀ = $4.653 \times 10^{-6} \pm 1.528 \times 10^{-8}$ mg/mL). The nature of the Eeth 70% bioactive compounds could justify the high anti-candidotic activity compared to the other extracts. The activity of Eeth 70% is indeed due to alkaloids, saponins, steroids, terpenoids and tannins.

These ethano-soluble molecules, which were moderately concentrated in this extract, were then able to express their anticandidotic potential better, hence the activity obtained.

Alkaloids, for example, generally have an important function in biological structures; they are also potent anticholinergics and are known for their high antibacterial potency^{56; 57}. The activity of Eeth 70% is attributed in part to the alkaloids which not only are concentrated in Eeth 70% but also possess strong antifungal activity according to the literature. An analysis of the CMI values shows that Eeth 70% enhances anticandidotic activity than the other extracts.

We recall that the activity of a plant substance depends on several factors including the mode of extraction and the concentration of active ingredient^{58; 59}.

The activity report (CMF/CMI) of Eeth 70% for *C. albicans* is one (1). The Eeth 70% thus has a fungicidal activity against *C. albicans*. This extract can therefore be described as a fungicidal substance. When the activity ratio (CMF/MIC) of an antimicrobial substance is less than or equal to four (≤ 4), the latter is referred to as a fungicidal substance and if the CMF/MIC ratio is greater than four (> 4), then it is called fungistatic⁶⁰.

4. CONCLUSION AND PERSPECTIVES

This analytical study, which consisted in demonstrating bioactive compounds and evaluating the superficial anticandidotic activity of five crude extracts of *Combretum racemosum*, makes it possible to conclude that all the extracts analyzed contain bioactive compounds at various degrees of concentration. The macerated hydro-ethanolic crude extract 70% (Eeth70%) contains, in medium concentrations, the same compounds mentioned above.

The *C. albicans* strain studied is sensitive to the five extracts tested. This sensitivity is different depending on the extract. *C. albicans* is more sensitive to Eeth 70%, while it is more resistant to macerated hydro-ethyl acetate crude extract 70% (Eace 70%). Eeth 70% of *C. racemosum* is the most active fraction on *C. albicans*. It concentrates the active ingredients better.

Taking into account the results obtained in this work, Eeth 70% could, after toxicological studies, be used as phytomedicine to combat skin, mucosal and skin apposition in humans.

In our future work, we will first prepare the partitioned extract of the Eeth 70% of *C. racemosum*, then purify its phytomolecules which we will test again on *C. albicans*. Finally, we will be interested in the toxicological study of Eeth 70% on laboratory animals.

REFERENCES

1. Scott DW, Miller WH and Griffin CE: Muller & Kirk's Small Animal Dermatology. 6th Edition Saunders 2001, 1552p.
2. Coulaud JP: Infections parasitaires et fongiques au cours du SIDA. Abstract, Euromedecine Montpellier 1987, 535-536.
3. Vandeputte P: Mécanismes moléculaires de la résistance aux antifongiques de *Candida glabrata*. Université d'angers. Thèse de doctorat, 2008, n°930.
4. Sellami H et ayadi H: Etude de la sensibilité des différentes espèces de *Candida*. Rev. Tun Infectiol 2008; 2 (2):1-79.
5. Piens MA, Monbrison de F et Picot S: Etude de la sensibilité des levures aux antifongiques en pratique médicale, let Infection 2003, XVIII n°6: 222-226.
6. Djohan VKE, Angora AH et Vanga-Bosson et coll: Sensibilité in vitro des souches de *Candida albicans* d'origine vaginale aux antifongiques à Abidjan (Côte d'Ivoire). J. mycol. Méd. 2011; 22(2):129-133
7. Tra Bi FH, Kouamé NG, Favel A et Fallague K : Activité antifongique de quelques plantes de la flore ivoirienne. Sciences et Nature 2007; 4(2):117-122.
8. Zhang W and Björn: The effect of ultraviolet radiation on the accumulation of medicinal compounds in plants Fitoterapia 2009; 80(4):207-218.
9. Borgers M, Degreef H and Cauwenbergh G: Fungal infections of the skin: infection process and antimycotic therapy Curr Drug Targets 2005; 6:849-862.
10. Eholie SP: Etude des infections opportunistes au cours du SIDA, à propos de 262 cas diagnostiqués, Thèse. Dipl. d'Etat Médecine, Abidjan 1993, n°1517: 81p.
11. De Souza C, Koumaglo K et Gbeassor M : Evaluation des propriétés antimicrobiennes des extraits totaux de quelques plantes médicinales. Rev. Méd. et pharm. Afr. 1995, Numéro spécial, 103-112.
12. Dosso M, Aissi H, Faye K, Saracino J et Kadio A: Evaluation de la sensibilité des bactéries hospitalières en zone tropicale à propos de 2543 souches de bacilles gram négatif isolées au CHU de Cocody, Méd. Mal. Infec. 1986; 6(4):241-244.
13. Matsuda Y, Sugiura K, Hashimoto T, Ueda A, Konno Y and Tatsumi Y: Efficacy coefficients determined using nail permeability and antifungal activity in keratin-containing media are useful for predicting clinical efficacies of topical drugs for onychomycosis, PLoS ONE, 2016, 11p.

14. Bennet MD, Bhandol P and Leitch JJ: Nuclear DNA amounts in angiosperms and their modern Uses 807 new estimates. *Annals of Botany* 2000; 86:859-909.
15. Wingard JR. and Leather H: A new era of antifungal therapy. *Biology of Blood and Marrow Transplantation* 2004; 10:73-90.
16. Odds FC, Brown AJP, Gow NAR: Antifungal agents: Mechanisms of action. *Trends in Microbiology* 2003; 11:272-279.
17. Li L, Naseem S, Sharma S and Konopka JB: Flavodoxin-Like Proteins Protect *Candida albicans* from Oxidative Stress and Promote Virulence. *PLoS Pathog.* 2015; 11(9).
18. Dupont B, Dromer F and Improvisi L: The problem of azole resistance in *Candida*. *J. Mycol. Med.* 1996; 6p.
19. Ferrari J: Contribution à la connaissance du métabolisme secondaire des Thymelaeaceae et investigation phytochimique de l'une d'elles: *Gnidia involucrate* Steud, ex A. Rich., Thèse de doctorat, Lausanne 2002.
20. Bahorun T: Substances naturelles actives: la flore mauricienne, une source d'approvisionnement potentielle. *Food and agricultural research council* 1997, 83-94
21. Marfak A: Radiolyse gamma des flavonoïdes, étude de leur réactivité avec les radicaux issus des alcools: formation de depsides, Thèse de doctorat, Limoges 2003, 181p.
22. World Organization of Health: A report of the consultation meeting on traditional and modern medicine: Harmonizing two approaches, Beijing, China 2000; 22-26.
23. De Morais Lima GR., De Sales IR, Caldas Filho MR, De Jesus NZ, De Sousa FH, Barbosa-Filho JM, Guedes Silveira Cabral A, Souto Lope A, Fachine Tavares J et Batista LM : Bioactivités du genre *Combretum* (Combretaceae): Un examen, en molécules 2012; 17:9142-9206.
24. Stace C A: Les familles et Généralités des plantes vasculaires. Springer, Berlin Heidelberg 2007; 9:67-82.
25. Burkill HM: The useful plants of West Tropical Africa. Royal Botanical Gardens, Kew 2000; 5:378p.
26. Oghenejobo M, Oghenejobo BUS, Uvieghara KE and Omughele E: Phytochemical screening and antimicrobial activities of the fractionated leaf extract of *Combretum racemosum*, Scholars. *Academic Journal of Pharmacy* 2014; 3(6):455-462.
27. Burkill HM: The useful plants of West Tropical Africa. Royal Botanical garden 1985; 5:378p.
28. Mpona M: Cours de Mycologie, 3 ème graduat ISTM/KIN/Labo Inéit 2008.
29. Fidel PL and Sobel JD: Immunopathogenesis of recurrent vulvovaginal candidiasis. *Clin. Microbiol. Rev.* 1996; 9:335-348.
30. Béné K, Camara D, Fofié N'GBY et Zirihi GN: Etude ethnobotanique, activité antifongique in-vitro sur *Candida albicans* et toxicité sur les cellules HFF de *Hirizonia abyssinica* Oliv. (Simaroubaceae), une plante de la pharmacopée ivoirienne. *Journal of Applied Biosciences* 2015; 94:8815-8824.
31. Zirihi GN, Kra AKM et Guédé-Guina F : Evaluation de l'activité antifongique de *Microglossa pyrifolia* (Lamarck) O kuntze (Asteraceae) "pymi" sur la croissance in vitro de *Candida albicans*. *Revue Méd. Pharm. Afr.* 2003; 17:11-189.
32. Ackah AJ, Kra, AM, Zirihi GN et Guédé-Guina F: Evaluation of the antifungal activity of TEKAM, évaluation de l'activité antifongique de tekam, un extrait de plante, sur la croissance in vitro de *candida albicans*. *Rev. Ivoir. Sci. Technol.* 2008; 11:119-129.
33. A. GUEDE: Etude des effets physiologiques d'un extrait aqueux de *Landolphia hirsuta* (Apocynacée), traditionnellement utilisé comme antihémorroïdaire et essai de formulation de suppositoires à effet antihémorroïdaire, Thèse de doctorat en pharmacie – UFR de Pharmacie d'Abidjan, N° 815/03, 2003, 200p.
34. Mangambu MJ, De D, Mushagalusa KF et Kadima NJ: Contribution à l'étude phytochimique de quelques médicinales antidiabétiques de la ville de Bukavu et ses environs (Sud-Kivu, R. D. Congo). *Journal of Applied Biosciences* 2014; 75: 6211-6220.
35. Yayé YG, Ackah JAAB, Kra AKM and Djaman JA: Anti-Fungal Activity of Different Extracts of *Terminalia Mantaly* H. Perrier on the in vitro Growth of *Aspergillus fumigatus*. *Eur. J. Sc. Res.* 2012, 82: 132-138.
36. Ackah JAAB, Yayé YG, Yapi HF, Kra AKM and Djaman AJ: Antifungal activity of *Terminalia mantaly* on the in vitro Growth of *Cryptococcus neoformans*. *International Journal of Biochemistry Research & Review* 2013; 3(1):63-73.
37. Ackah AJ, Kra AM, Zirihi GN et Guédé-Guina F: Evaluation de l'activité antifongique de tekam, un extrait de plante, sur la croissance in vitro de *candida albicans*. *Rev. Ivoir. Sci. Technol.* 2008; 11:119-129.
38. Guédé-Guina F, Wangah-Manda M, Bonga GM et De Sousa C: Activité antimicrobienne d'un extrait végétal contre les germes opportunistes au cours du SIDA. *Rev. Méd. Pharm. Afr.* 1995; 9(1):13-19.
39. Kra AKM: Evaluation et amélioration par séquençage chromatographique d'une action antifongique de MISCa contre *Aspergillus fumigatus*. Thèse de doctorat de 3 ème cycle; Option: Pharmacologie-Microbiologie. Université de Cocody, U.F.R. Biosciences. Abidjan, Côte d'Ivoire, 2001, 116p.
40. Harbone JP: Méthodes phytochimiques, 2nd Ed., Dakota du Nord Oxford Université Presse, Londres 1991.
41. Onocha PA, Audu EO, Ekundayo O and Dosumu OO: Phytochemical and antimicrobial properties of extracts of *Combretum racemosum*. *Acta Horticulturae* 2005a; 675:2-97.
42. Okwuosa CN, Achukwu PUO, Azubike NC et Abah AIE: Effet de protection des extraits de feuilles de *Combretum racemosum* P. Beauv (Combretaceae) sur la Pancytopenie et la lésion hépatique induite par Cyclophosphamide chez les rats mâles. *Research Journal of Pharmacology* 2012; 6: 30-34.
43. Kamou KR, Ouattara K, Bagré I, Gnahoué G, Ouattara A et Coulibaly A : Screening phytochimique et activités antifongiques d'extraits de *Combretum racemosum* (P. Beauv.) sur cinq souches fongiques cliniques. Thèse de doctorat en Biotechnologies, UFR des Biosciences d'Abidjan. *Journal Mondial de la Recherche Pharmaceutique*, 2016, 5(10): 119-126.
44. Cowan MM: Plant products as antimicrobial agents. *Clin. Microbiol. Rev.* 1999; 12(4):564-582.
45. Chodera A, Dabrowska A, Sloderbach A, Skrzypczak L, Budzianowski J: Effect of flavonoid fractions of *Solidago virgaurea* L. on diuresis and levels of electrolytes. *Acta Pol Pharm.* 1991; 48: 35-37.
46. Rizvi SH, Shoeb A, Kapil RS, Popli PS: Two diuretic triterpenoids from *Antidermanthus*. *Phytochemistry* 1980, 19(11): 2409-2410.
47. McGaw LJ, Rabe T, Sparg SG, Jager AK, Eloff JN and Van Staden J: An investigation on the biological activity of *Combretum* species. *Journal of Ethnopharmacology* 2001; 75:45-50.
48. Onocha PA, Audu EO, Ekundayo O and Dosumu OO: Phytochemical and antimicrobial properties of extracts of *Combretum racemosum*. *Acta Horticulturae* 2005b, 675: 2-97.
49. Okwuosa OMTB, Chukwura EL, Chukwuma GO, Enweani IB, Agbakoba NR, Chukwuma CM, Manafa PO et Umedum CU: Activités phytochimiques et antifongiques des feuilles et racines d'*Uvaria chamae*, des feuilles et écorces de *Spondias mombi* et des feuilles de *Combretum racemosum*, suppl. *Afr. J. Med. Sci.* 2012; 41: 99-103.

50. Faizi S, Rashid M, Alik RA, Ahmed S, Khan SA, Aqeel AA, Bibi N et Ahmed SA: Évaluation de propriété antimicrobienne de *Polyalthia longifolia* var. *Pendula*: isolement d'une lactone comme l'agent antibactérien actif de l'extrait d'éthanol de la tige. *Phytother, Res.* 2003; 17(10):1177-1181.
51. Scalbert: Propriétés antimicrobiennes des tannins, *Phytochimie* 1991, 30: 3875-3883.
52. Cimanga K, Kambu K, Tona L and Hermans N et al.: Cytotoxicity and in vitro susceptibility of *Entamoeba histolytica* to *Morinda morindoides* leaf extracts and its isolated constituents. *Journal of Ethnopharmacology* 2006; 107: 83-90.
53. Mankele R, Ouamba JM, Abena AA et Yalaf A: Étude des effets de *Morinda morindoides* (Back) sur le système immunitaire de l'homme. *Phytothérapie* 2006; 4(2): 68-73.
54. Koechlin-Ramonatxo C: Oxygen, oxidative stress and antioxidant supplementation, or another way of nutrition in respiratory diseases. *Nutr. Clin. et Métab.* 2006; 20:165-177.
55. Suhaj M: Spice antioxidants isolation and their antiradical activity: a review. *J. Food Compos. and Analys.* 2006, 19: 531-537.
56. Scazzocchio F, Comata MF, Tomassini L and Palmery M, Antibacterial activity of *Hydrastis canadensis* extract and its major isolated alkaloids. *Planta medica* 2001; 67(6):561-564.
57. Muster D, Lotfi BS: Thérapeutique médicale buccodentaire: moyens et methods Publié par Elsevier Masson, ISBN 2842995651, 9782842995652, 2004, 290p.
58. Wagner H: *Pharmazeutische Biologie. Drogen und ihre Inhaltsstoffe*, Gustav Fisher Verlag, Stuttgart-New-York 1993, 522p
59. Thangara JHS, Adjei O, Allen BW and Portaels F et al.: In vitro activity of ciprofloxacin, Sparfloxacin, Ofloxacin, Amikacin and Rifampicin against Ghanaian isolates of *Mycobacterium ulcerans*, agents *Chemother. J. Antimicrob.* 2000; 45 (2):231-233.
60. Marmonier AA: Introduction aux techniques d'étude des antibiotiques, *Bactériologie Médicale, technique usuelles* 1990; 227-236.

